CUVL

Clinuvel Pharmaceuticals Ltd ADR

4.97

Nov 13 • 3:43 PM ET -0.08 (-1.58%)

5.05

Aftermarket • 6:46 PM ET +0.08 (1.61%)

Healthcare Biotechnology Australia Micro NASD

Peers: IRON PTN RYTM ABEO FENC KRYS INCY ARQT SNGX VRCA

Scroll to Statements

Index	-
Market Cap	250.94M
Enterprise Value	77.66M
Income	23.33M
Sales	64.31M
Book/sh	3.75
Cash/sh	3.46
Dividend Est.	0.04 (0.77%)
Dividend TTM	0.04 (0.72%)
Dividend Ex-Date	Sep 08, 2026
Dividend Gr. 3/5Y	0.00% 24.57%
Payout	6.19%
Employees	-
IPO	Jul 02, 2004

P/E	10.81
Forward P/E	10.10
PEG	0.89
P/S	3.90
P/B	1.33
P/C	1.44
P/FCF	10.11
EV/EBITDA	2.71
EV/Sales	1.21
Quick Ratio	14.45
Current Ratio	14.81
Debt/Eq	0.01
LT Debt/Eq	0.01
Option/Short	No / Yes

EPS (ttm)	0.46
EPS next Y	0.49
EPS next Q	0.18
EPS this Y	-0.97%
EPS next Y	3.44%
EPS next 5Y	11.32%
EPS past 3/5Y	3.32% 4.25%
Sales past 3/5Y	6.54% 12.24%
EPS Y/Y TTM	-0.47%
Sales Y/Y TTM	5.04%
EPS Q/Q	16.80%
Sales Q/Q	6.50%
Earnings	Aug 26 AMC
EPS/Sales Surpr.	0.91% -1.62%

Insider Own	-
Insider Trans	-
Inst Own	0.11%
Inst Trans	-8.30%
ROA	12.16%
ROE	13.45%
ROIC	12.27%
Gross Margin	82.84%
Oper. Margin	43.47%
Profit Margin	36.28%
SMA20	-1.85%
SMA50	-9.34%
SMA200	-26.73%
Trades

Shs Outstand	50.43M
Shs Float	37.77M
Short Float	0.01%
Short Ratio	0.15
Short Interest	0.00M
52W High	8.92 -44.28%
52W Low	4.81 3.33%
Volatility	2.34% 4.36%
ATR (14)	0.23
RSI (14)	40.27
Beta	0.89
Rel Volume	0.03
Avg Volume	13.28K
Volume	370

Perf Week	-2.55%
Perf Month	-1.78%
Perf Quarter	-27.71%
Perf Half Y	-27.34%
Perf YTD	-41.39%
Perf Year	-30.00%
Perf 3Y	-50.10%
Perf 5Y	-79.10%
Perf 10Y	-20.35%
Recom	2.14
Target Price	11.80
Prev Close	5.05
Price	4.97
Change %	-1.58%

Aug-27-26 01:42AM	A decade of profitability provides foundation for CLINUVEL's U.S. expansion (GlobeNewswire) -11.44%
Jul-23-26 12:10AM	CLINUVEL implements strategic reorganisation to refocus on U.S. markets (GlobeNewswire)

Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The firm engages in the development of SCENESSE, its proprietary photoprotective drug. It also offers drugs for the treatment of various skin disorders. The company was founded by Robert Thomas Dorr on December 14, 1999 and is headquartered in Melbourne, Australia.

M.D.Dr. Philippe Jacques Wolgen M.B.A.

Chief Financial OfficerMr. Peter Vaughan

Chief Operations OfficerMr. Lachlan Hay

M.Sc.Dr. Dennis J. Wright BPharm

Head of Australian Operations & Investor RelationsMr. Malcolm Bull

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

All the Features.Half the Price.

CUVL

Clinuvel Pharmaceuticals Ltd ADR

Upgrade your Finviz experience

All the Features.
Half the Price.